Browsing Category

45560 posts

Akeso Announces FDA Approval for Penpulimab-kcqx in Two BLA Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma

HONG KONG, April 25, 2025 /PRNewswire/ — Akeso, Inc. (9926.HK) ("Akeso" or…
A Visionary Breakthrough: VISTA Eye Specialist and EssilorLuxottica Join Forces to Combat Childhood Myopia in Malaysia

A Visionary Breakthrough: VISTA Eye Specialist and EssilorLuxottica Join Forces to Combat Childhood Myopia in Malaysia

PETALING JAYA, Malaysia, April 25, 2025 /PRNewswire/ — In a landmark move…
Global Media Witnesses Chery Super Hybrid (CSH)'s Breakthrough as 'Endless Horizon Worry-Free Voyage' Endurance Challenge Completes First Stage

Global Media Witnesses Chery Super Hybrid (CSH)'s Breakthrough as 'Endless Horizon Worry-Free Voyage' Endurance Challenge Completes First Stage

SHANGHAI, April 25, 2025 /PRNewswire/ — On April 23, coinciding with the…
ZERO BREEZE Partners with NASCAR Driver Patrick Emerling to Bring Cooling Innovation to the Track

ZERO BREEZE Partners with NASCAR Driver Patrick Emerling to Bring Cooling Innovation to the Track

LINCOLN, Ala., April 25, 2025 /PRNewswire/ — ZERO BREEZE, a leader in portable…

Theo Raises $20M to Democratize Access to Institutional-Grade Trading Infrastructure

Founded by ex-Optiver and IMC quants, the platform is backed by angels…

Atomicwork launches its Universal Agent, bringing Multimodal AI to every employee's flow of work

This first-of-its-kind Universal Agent eliminates manual work with Voice and Vision AI…
Lionsgate's 'Now You See Me: Now You Don't' Brings Some of Its Movie Magic to Abu Dhabi in Collaboration with Abu Dhabi's Creative Media Authority, Abu Dhabi Film Commission and Miral Destinations

Lionsgate's 'Now You See Me: Now You Don't' Brings Some of Its Movie Magic to Abu Dhabi in Collaboration with Abu Dhabi's Creative Media Authority, Abu Dhabi Film Commission and Miral Destinations

ABU DHABI, UAE, April 25, 2025 /PRNewswire/ — Abu Dhabi residents might…

VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Non-Infectious Anterior Uveitis

VVN461, a dual JAK1/TYK2 inhibitor as a non-steroidal anti-inflammatory agent, has met…